Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in…
Conference Call Scheduled for July 6, 2023 at 11:00 am EASTERNDUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:…
CARLSBAD, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management…
HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T…
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients…
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants…
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26,…
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…